Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Comment by zenvestingon Nov 30, 2015 7:12pm
145 Views
Post# 24340517

RE:RE:Silvercoat being released into a strong market

RE:RE:Silvercoat being released into a strong marketThe total Foley catheter market is estimated at $500M in 2015, with antimicrobial estimated to be close to $290M of that market in this Frost & Sullivan report written in 2011 and based on 2009 projections: https://www.academia.edu/7673287/U._S._Urinary_Incontinence_Devices Interestingly, this report indicates that Medline's Silvertouch Foley catheter had reached 2% market penetration after its 2009 introduction. As we all should know, that product is licensed from Covalon and I believe is substantially equivalent to the Silvercoat Foley catheter Covalon will be marketing. This white paper from Medline makes a pretty good case for it being better than the "competition": https://www.medline.com/irj/servlet/prt/portal/prtroot/pcd!3aportal_content!2fmedline!2fGlobal!2fPublicDocs/publicdocuments/Medline%20Documents/Marketing%20Materials/MarketingDocuments_N-Z/SIlvertouch%20Brochure%20MKT210104%20LIT498.pdf I am quite excited about the possibilities this opens up for our little company.
Bullboard Posts